| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/26/2000 | EP0995439A1 Use of indazole derivatives in the manufacture of a medicament for treating congestive heart failure |
| 04/26/2000 | EP0995437A1 2,3-dihydrobenzofuran derivatives |
| 04/26/2000 | EP0995436A2 Ligands for sigma receptors and their therapeutical applications |
| 04/26/2000 | EP0995433A1 Retinol stabilized cleansing compositions |
| 04/26/2000 | EP0995422A1 Use of nitrilotriacetic acid for stabilizing of flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them |
| 04/26/2000 | EP0995120A1 Protein elongation factor 2 as a target for antifungal and antiparasitic agents |
| 04/26/2000 | EP0995118A1 Chaperone fragments |
| 04/26/2000 | EP0994948A1 TGF$g(b) RII RECEPTOR NUCLEIC SEQUENCE, CODED PEPTIDE, AND USES |
| 04/26/2000 | EP0994945A2 Smad-interacting polypeptides and their use |
| 04/26/2000 | EP0994890A2 Benzimidazole derivatives |
| 04/26/2000 | EP0994889A2 Erythromycin a oxime solvates |
| 04/26/2000 | EP0994888A1 Process for the acylation of amino alcohols |
| 04/26/2000 | EP0994887A2 Modified glycosides, compositions comprised thereof and methods of use thereof |
| 04/26/2000 | EP0994884A1 Diphosphonic acid salts for the treatment of osteoporosis |
| 04/26/2000 | EP0994880A1 Crystalline macrolides and process for their preparation |
| 04/26/2000 | EP0994878A1 Quinolone carboxylic acid derivatives |
| 04/26/2000 | EP0994877A1 Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| 04/26/2000 | EP0994876A1 Quaternary ammonium compounds as tachykinin antagonists |
| 04/26/2000 | EP0994875A1 3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cns disorders |
| 04/26/2000 | EP0994874A1 Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents |
| 04/26/2000 | EP0994873A1 Substituted 1h-pyridinyl-2-ones as gaba a?alpha 2/3 ligands |
| 04/26/2000 | EP0994872A1 4-phenylpiperidine compounds |
| 04/26/2000 | EP0994870A1 Novel aryloxy substituted pyrimidine imidazole compounds |
| 04/26/2000 | EP0994869A1 5-(2-ETHYL-2$i(H)-TETRAZOL-5-Y1)-1-METHYL-1,2,3,6-TETRAHYDROPYRIDINE MALEATE |
| 04/26/2000 | EP0994867A1 Polymorphic form of the tachykinin receptor antagonist 2-(r)-(1-(r) -(3,5-bis(trifluoromethyl) phenyl)ethoxy)-3-(s)-(4-fluoro) phenyl-4-(3-5 (-oxo-1h,4h-1,2,4,-triazolo) methylmorpholine |
| 04/26/2000 | EP0994866A1 5-(3-phenyl-3-oxo-propyl)-1h-tetrazole derivatives |
| 04/26/2000 | EP0994865A1 Triazole compounds and the use thereof as dopamine-d 3?-ligands |
| 04/26/2000 | EP0994864A1 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
| 04/26/2000 | EP0994863A1 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
| 04/26/2000 | EP0994862A2 Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
| 04/26/2000 | EP0994861A1 NEW $g(b)-AMINO AND $g(b)-AZIDOCARBOXYLIC ACID DERIVATIVES, THE PRODUCTION THEREOF AND THE USE THEREOF AS ENDOTHELIN RECEPTOR ANTAGONISTS |
| 04/26/2000 | EP0994860A1 Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| 04/26/2000 | EP0994859A1 Compounds |
| 04/26/2000 | EP0994858A1 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| 04/26/2000 | EP0994857A1 (1h-imidazol-4-yl)piperidine derivatives, preparation and application in therapy |
| 04/26/2000 | EP0994856A1 Inhibitors of farnesyl protein transferase |
| 04/26/2000 | EP0994854A1 Method for preparing a substituted perhydroisoindole |
| 04/26/2000 | EP0994853A2 Compounds and methods for the inhibition of the expression of vcam-1 |
| 04/26/2000 | EP0994743A1 Treatment of inflammatory disorders of the bowel and urinary bladder |
| 04/26/2000 | EP0994728A1 Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
| 04/26/2000 | EP0994727A1 Process for solubilizing pharmaceutically active ingredients in water and in aqueous vehicles |
| 04/26/2000 | EP0994717A1 Treatment of autoimmune disease using tolerization in combination with methotrexate |
| 04/26/2000 | EP0994716A1 Maternal immune secretions and their use in the treatment and/or prophylaxis of conditions of the human body |
| 04/26/2000 | EP0994715A1 Difluoronucleoside phosphonic acids and derivatives thereof |
| 04/26/2000 | EP0994714A1 Use of compositions containing the combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine |
| 04/26/2000 | EP0994713A1 USE OF A 7$g(a)-METHYL-17$g(a)-ETHYNYL-ESTRANE DERIVATIVE FOR THE TREATMENT OF ATHEROSCLEROSIS |
| 04/26/2000 | EP0994712A1 Inhibitors of neutrophil mediated oxidant production |
| 04/26/2000 | EP0994711A1 Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and rnal function |
| 04/26/2000 | EP0994710A1 Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin |
| 04/26/2000 | EP0994709A1 Calcium blockers to treat proliferative vitreoretinopathy |
| 04/26/2000 | EP0994708A1 Antagonists of gonadotropin releasing hormone |
| 04/26/2000 | EP0994707A1 Inhibitors of naaladase enzyme activity |
| 04/26/2000 | EP0994706A1 Method and compositions for administering taxanes orally to human patients |
| 04/26/2000 | EP0994705A1 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
| 04/26/2000 | EP0994704A1 Use of gaba analogs such as gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| 04/26/2000 | EP0994703A2 Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps |
| 04/26/2000 | EP0994702A2 Medicament comprising adenosine |
| 04/26/2000 | EP0994701A1 Block copolymer |
| 04/26/2000 | EP0994699A1 Controlled release dosage forms containing water soluble drugs |
| 04/26/2000 | EP0994697A1 Rapamycin formulations for oral administration |
| 04/26/2000 | EP0994696A1 Controlled release pharmaceutical preparation with ace inhibitor as active agent |
| 04/26/2000 | EP0994693A2 Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin |
| 04/26/2000 | EP0994657A1 Palatable elemental medical food |
| 04/26/2000 | EP0994655A1 Satiety product |
| 04/26/2000 | EP0983037A4 Antifungal nail lacquer and method using same |
| 04/26/2000 | EP0963201A4 Transdermal application of naturally occurring steriod hormones |
| 04/26/2000 | EP0865291A4 Localized intravascular delivery of tfpi for inhibition of restenosis in recanalized blood vessels |
| 04/26/2000 | EP0802913B1 IMIDAZO [4,5-c]QUINOLINE AMINES |
| 04/26/2000 | EP0787121B1 Legionella specific antibiotic, a microorganism producing the antibiotic and a process for producing the same |
| 04/26/2000 | EP0777671B1 Spiro-azabicyclic compounds useful in therapy |
| 04/26/2000 | EP0771209A4 Novel peptides |
| 04/26/2000 | EP0766963B1 Arteriosclerosis depressant |
| 04/26/2000 | EP0738269B1 Piperidine derivatives with paf antagonist activity |
| 04/26/2000 | EP0736020B1 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| 04/26/2000 | EP0735884B1 Flunisolide aerosol formulations |
| 04/26/2000 | EP0703909B1 Delta 6,7 -taxols antineoplastic use and pharmaceutical compositions containing them |
| 04/26/2000 | EP0686035B1 Agent for prophylaxis or treatment of cataract |
| 04/26/2000 | EP0683780B1 Imidazopyridines and their use in treating gastrointestinal diseases |
| 04/26/2000 | EP0680469B1 Aminoacid derivates, medicaments containing these compounds and process for preparing the same |
| 04/26/2000 | EP0680318B1 Method for increasing the efficiency of feed conversion in animals |
| 04/26/2000 | EP0670826B1 Fatty acid derivatives and pharmaceutical compositions containing them |
| 04/26/2000 | EP0661271B1 Azepine derivatives, production thereof, and use thereof as sigma-receptor ligands |
| 04/26/2000 | EP0626853B1 Use of substituted adenine derivatives for treating multiple sclerosis |
| 04/26/2000 | EP0559700B1 Novel pilocarpine derivatives and process for their preparation |
| 04/26/2000 | EP0554247B1 Neuroprotective indolone and related derivatives |
| 04/26/2000 | EP0507872B1 The use of arginine as an immunostimulator |
| 04/26/2000 | CN1251612A Novel compound |
| 04/26/2000 | CN1251592A Nucleotide analog composation |
| 04/26/2000 | CN1251591A Antibacterial substituted 7-acylamino-3 (methylhydrazono) methyl-cephalosporins and intermediates |
| 04/26/2000 | CN1251590A Crystalline amine salt of cefdinir |
| 04/26/2000 | CN1251589A Substituted triazolo-pyridazine derivatives as ligands for GABA receptors |
| 04/26/2000 | CN1251588A Novel 3,5 and/or 6 substituted analogues of swainsonine, process for their preparation and their use as therapeutic agents |
| 04/26/2000 | CN1251587A Pyrrolidine derivatives having phospholipase A inhibitory activity |
| 04/26/2000 | CN1251586A Noval pyrimidine derivatives and process and preparing thereof |
| 04/26/2000 | CN1251579A Compound and compositions for treating diseases associated with serine protease, particularly tryptase, activity |
| 04/26/2000 | CN1251574A Process for preparing O-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides |
| 04/26/2000 | CN1251573A Solid composition suitable for oral administration comprising non hydroscopic salts of L-carnitine or alkanoyl-L-carnitine with 2-aminoethanesulfonic acid |
| 04/26/2000 | CN1251572A Solid compositions suitable for oral administration composing L-carnitine and alkanoyl-L-carnitine mangesium tartrate |
| 04/26/2000 | CN1251569A Noval compounds, their use and preparation |
| 04/26/2000 | CN1251530A Use of substaces having oxytocin activity for preparation of medicaments for wound healing |